- Home
- AIRI vs HOOK Comparison
AIRI vs HOOK Comparison
Compare AIRI & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- HOOK
- Stock Information
- Founded
- AIRI 1979
- HOOK 2011
- Country
- AIRI United States
- HOOK United States
- Employees
- AIRI N/A
- HOOK N/A
- Industry
- AIRI Military/Government/Technical
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- HOOK Health Care
- Exchange
- AIRI Nasdaq
- HOOK Nasdaq
- Market Cap
- AIRI 13.4M
- HOOK 15.3M
- IPO Year
- AIRI N/A
- HOOK 2019
- Fundamental
- Price
- AIRI $3.29
- HOOK $1.20
- Analyst Decision
- AIRI
- HOOK Buy
- Analyst Count
- AIRI 0
- HOOK 4
- Target Price
- AIRI N/A
- HOOK $10.67
- AVG Volume (30 Days)
- AIRI 45.6K
- HOOK 67.1K
- Earning Date
- AIRI 08-13-2025
- HOOK 08-07-2025
- Dividend Yield
- AIRI N/A
- HOOK N/A
- EPS Growth
- AIRI N/A
- HOOK N/A
- EPS
- AIRI N/A
- HOOK N/A
- Revenue
- AIRI $53,182,000.00
- HOOK $9,351,000.00
- Revenue This Year
- AIRI $5.59
- HOOK N/A
- Revenue Next Year
- AIRI $5.00
- HOOK N/A
- P/E Ratio
- AIRI N/A
- HOOK N/A
- Revenue Growth
- AIRI 0.29
- HOOK N/A
- 52 Week Low
- AIRI $3.00
- HOOK $0.72
- 52 Week High
- AIRI $9.44
- HOOK $6.77
- Technical
- Relative Strength Index (RSI)
- AIRI 41.01
- HOOK 39.18
- Support Level
- AIRI $3.33
- HOOK $1.13
- Resistance Level
- AIRI $3.39
- HOOK $1.35
- Average True Range (ATR)
- AIRI 0.14
- HOOK 0.06
- MACD
- AIRI -0.01
- HOOK -0.01
- Stochastic Oscillator
- AIRI 6.25
- HOOK 40.64
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.